Replies to post #156544 on Biotech Values

[masterlongevity]

its not surprising. this was a great deal for BIIB, and no one trusts Elan's mgmt with that much cash.

[DewDiligence]

BIIB/ELN—I don't recall seeing such a big upfront payment in a buyout of a drug before granted its a very high revenue drug.

Well, it’s not a direct comparable but PFE paid $90B to acquire Warner-Lambert for essentially one drug: Lipitor.